2010

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

Top

The effects of salsalate on glycemic control in patients with type 2 diabetes a randomized trialGoldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE for the TINSAL T2D Study Team. Ann Intern Med. 2010 152 346 357. The Targeting Inflammation Using Salsalate* in Type 2 Diabetes (TINSAL-T2D) trial was a parallel, randomized, placebo-controlled multicenter trial evaluating the safety and efficacy of salsalate in subjects with type 2 diabetes.

Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry

Top

Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, Ng VW, Luk AO, Ozaki R, Tong PC, Chow CC, Chan JC. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010 Oct 1. [Epub ahead of print]. Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties. This study examined associations between use of sulphonylureas and cancer.

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

Top

D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.J Clin Endocrinol Metab. 2009;94(1):81-88. Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1).

The Munich Myocardial Infarction Registry: impact of C-reactive protein and kidney function on hospital mortality in diabetic patients

Top

Schnell O, Braun KF, Muller M, Standl E, Otter W. The Munich Myocardial Infarction Registry: impact of C-reactive protein and kidney function on hospital mortality in diabetic patients. Diab Vasc Dis Res. 2010;7(3)225-230. The aim of this study was to analyse hospital mortality with regards to the presence of diabetes, elevation of C-reactive protein (CRP) levels and impaired kidney function (IKF) on admission.

Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study

Top

Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care. 2009;32(7):1272-1273. To determine whether serum uric acid predicts incident type 2 diabetes by glucose tolerance status in older community-dwelling adults.

Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an ASCOT substudy

Top

Stettler C, Witt N, Tapp RJ, et al. Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy.. Diabetes Care. 2009;32(6):1098-1100. To study the association of the inflammatory markers serum amyloid A (SAA) and C-reactive protein (CRP) with retinal microvascular parameters in hypertensive individuals with and without type 2 diabetes.

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment

Top

Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study. Diabetes Res Clin Pract. 2010 July 22. [Epub ahead of print]. This retrospective analysis assessed safety and tolerability of vildagliptin (Vilda) as an add-on to metformin in type 2 diabetes mellitus (T2DM) patients with normal renal function (GFR >80mL/min/1.73m(2)) and mild renal impairment (GFR: >50 to =80mL/min/1.73m(2)). 

Prevalence of pre-diabetes, association with cardiometabolic risk factors and hyperinsulinemia among US adolescents: NHANES 2005-2006

Top

Li C, Ford ES, Zhao G, Mokdad AH. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006. Diabetes Care. 2009;32(2):342-347. Impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) are considered to constitute "pre-diabetes." We estimated the prevalence of IFG, IGT, and pre-diabetes among U.S. adolescents using data from a nationally representative sample.

Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD)

Top

McEwen LN, Bilik D, Johnson SL, et al. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). ACC Abstracts of the 48th Scientific Session. 2009;32(6):971-976. The purpose of this study was to examine the predictors of intensification of antihyperglycemic therapy in patients with type 2 diabetes; its impact on A1C, body weight, symptoms of anxiety/depression, and health status; and patient characteristics associated with improvement in A1C.

Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes

Top

Gatti A, Maranghi M, Bacci S, et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2009;32(8):1550-1552. To determine whether the association observed between poor glycemic control and low HDL cholesterol in type 2 diabetes is dependent on obesity and/or hypertriglyceridemia.

1 2 3 4 5 Next